Cardiac Consult
A Cleveland Clinic podcast exploring heart, vascular and thoracic topics of interest to healthcare providers: medical and surgical treatments, diagnostic testing, medical conditions, and research, technology and practice issues.
Subscribe:
Featured Episode
Long-term Risk of Heart Attack, Stroke and Death Doubles with History of COVID-19 Infection
The study found that people with any type of COVID-19 infection were twice as likely to have a major cardiac event, such as heart attack, stroke or even death, for up to three years after diagnosis. Stanley Hazen, MD, PhD summarizes the findings of this Cleveland Clinic led trial and implications for practice and future research.
Play NowAll Cardiac Consult Episodes
December 12, 2024
Talking Tall Rounds®: Cardiac Sarcomas
Eric Roselli, MD, provides an overview, a complex cardiac sarcoma case is presented by Holliann Willekes, MD, followed by an update on imaging modalities from Patrick Collier, MD, PhD, and a perspective on pathology from Marc Halushka, MD, PhD.
Play NowDecember 5, 2024
Diversity in Medicine
Lee Kirksey, MD, moderates a panel discussion on diversity in medicine with Miriam Jacob, MD, Milind Desai, MD, James Carter, MD, and Quinn Capers, MD, Visiting Professor from Howard University.
Play NowNovember 26, 2024
Oral Anticoagulation Compared to Left Atrial Appendage Closure Following Catheter Ablation: Results From the OPTION Trial
A Cleveland Clinic-led trial found that a minimally-invasive procedure – left atrial appendage closure (LAAC) – resulted in significantly less bleeding in patients undergoing a catheter ablation to treat atrial fibrillation, compared to oral anticoagulation, while preserving low rates of stroke, blood clots and death. The OPTION Trial was presented at the American Heart Association’s Scientific Sessions 2024. Walid Saliba, MD speaks with Oussama Wazni, MD, Section Head of Cardiac Electrophysiology and Pacing at Cleveland Clinic and Primary Investigator of the OPTION Trial, about the results of the trial and implications for practice.
Play NowNovember 20, 2024
Cardiac Imaging in the VALOR-HCM Trial
Mavacamten is the first and only FDA-approved cardiac myosin inhibitor to treat obstructive hypertrophic cardiomyopathy (HCM). An important factor to the success of the VALOR HCM trial was the participation of specialized cardiac sonographers and imagers. Milind Desai, MD, MBA speaks with Jeanne Drinko, Amy Kanta and Anne Campbell about the importance of cardiac imaging. Learn more about C5 Research at Cleveland Clinic.
Play Now
